Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 8/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862936 | 1.00 | SRC (0.36) | SRCACERENLMNACYP2C19 | |
| SCHEMBL26697144 | 1.00 | SRC (0.36) | SRCACERENLMNACYP2C19 | |
| SCHEMBL4859280 | 0.88 | ACE (0.49) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL18616038 | 0.88 | ACE (0.49) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL4866241 | 0.88 | ACE (0.49) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL17652360 | 0.86 | ACE (0.44) | ACEREN | |
| SCHEMBL4863667 | 0.86 | ACE (0.44) | ACEREN | |
| SCHEMBL18616806 | 0.86 | ACE (0.44) | ACEREN | |
| SCHEMBL7291397 | 0.82 | ATM (0.39) | SRCACE | |
| SCHEMBL31099325 | 0.82 | SRC (0.36) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | SRC 42/4885ACE 3760/4885REN 2317/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | SRC 42/4885ACE 3760/4885REN 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.